Insights

Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today

The global effort to defeat cancer continues, with this ASX healthcare share commencing a new clinical study.
The post Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today appeared first on The Motley Fool Australia. –

The Kazia Therapeutics Ltd (ASX: KZA) share price is edging lower, down 2% in morning trade.

Below we take a look at the oncology-focused drug development company’s latest clinical trial update.

What update did Kazia provide?

Kazia Therapeutics’ share price is sliding despite the company reporting that a phase II study of its investigational new drug paxalisib, has commenced at Dana Farber Cancer Institute in Boston, Massachusetts.

The first patient has now enrolled in the study, which is expected to recruit up to 25 patients and take up to 2 years to complete.

Paxalisib is intended to treat primary CNS lymphoma (PCNSL). Lymphoma, a cancer of white blood cells, can spread throughout the body, while PCNSL solely afflicts the brain and central nervous system. Paxalisib belongs to the PI3K inhibitor class.

According to the release, the incidence of PCNSL has been increasing with time. The company also notes that many drugs administered to treat lymphoma in other areas of the body don’t work for PCNSL, as they can’t cross the blood-brain barrier.

Lakshmi Nayak, principal investigator for the study said:

Our centre has a strong research focus in primary CNS lymphoma. We are very interested to explore the potential for a brain-penetrant PI3K inhibitor in this disease. Patient outcomes in PCNSL remain far from optimal, and there is a pressing need for new treatment options.

Kazia’s CEO, James Garner added:

With paxalisib now in an international pivotal study for glioblastoma, we are increasingly focused on identifying other groups of patients who may benefit from the drug. There is a very sound rationale to explore PCNSL in this disease, and we are looking forward to seeing the study progress.

Kazia said it will support the study by proving the study drug as well as a financial grant.

There are now 8 ongoing clinical studies of paxalisib in brain cancer.

Kazia Therapeutics share price snapshot

Over the past 12 months, Kazia’s shares have gained 220%, well outpacing the 20% gains posted by the All Ordinaries Index (ASX: XAO).

Year-to-date the Kazia Therapeutics share price is up 5%.

The post Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

ASX 200 down 0.1%: Altium rockets, NAB hit with AUSTRAC investigation

NAB (ASX:NAB) share price slumps as AUSTRAC begins investigation
Why the MNF (ASX:MNF) share price is up 6% today
Why the 88 Energy (ASX:88E) share price is plummeting 9% this morning
3 reasons Dogecoin could head to the moon — Someday

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!